EGFR and non-small cell lung carcinoma: Gefitinib and erlotinib, which are seen to be two small-molecule first-generation EGFR tyrosine kinase inhibitors (EGFR-TKI), were approved more than a decade ago and have been popularly used as a first-line treatment option for advanced NSCLC (Gelatti et al. 2019).